Without integrating into cellular DNA, a novel HIV-based lentiviral vector can introduce a gene to pancreatic tumor cells that makes them more sensitive to the chemotherapeutic drug gemcitabine.
This integrase-defective lentiviral delivery system greatly reduces the risk of insertional mutagenesis and replication-competent lentivirus production, as describe in a new study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free to read on the Human Gene Therapy website until March 31, 2016.
The article, "Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy," is part of a special issue of Human Gene Therapy focusing on advances in gene and cell therapy research in France, led by Guest Editors Nathalie Cartier, MD, Director of Research, INSERM, Paris, and President, European Society of Gene and Cell Therapy (ESGCT), and Pierre Cordelier, PhD, Senior Researcher, INSERM, Toulouse, France, and President, French Society of Cell and Gene Therapy (SFTCG). The special issue will be distributed at the SFTCG meeting, March 9-11, Marseilles, France.
"Pancreatic cancer remains one of the most dreaded diagnoses a patient can receive," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Edu-cation and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. Gene therapy offers hope when no other options may exist.